TABLE 2.
Piperacillin bootstrap results
| Parameter | Structural model (RSE %)a [shrinkage%] | Final model data |
||
|---|---|---|---|---|
| Final model (RSE %) [shrinkage %] | Bootstrap (5,000 replicates) |
|||
| Median | 95% CI (2.5%–97.5%) | |||
| Fixed effects | ||||
| ΘCL | 7.9 (11) | 9.4 (7) | 9.601 | 8.307, 11.43 |
| ΘV1 | 11.1 (23) | 6.56 (18) | 7.824 | 3.038, 14.52 |
| ΘV2 | 13.3 (19) | 14.2 (14) | 12.70 | 9.095, 17.04 |
| ΘQ | 16.3 (32) | 17.2 (22) | 14.53 | 7.318, 23.92 |
| ΘECMO | –0.092 (33) | –0.099 | –0.170, –0.020 | |
| ΘCrCL | 0.115 (17) | 0.120 | 0.051, 0.166 | |
| ΘCVVHDF | 1.46 (40) | 1.837 | 0.076, 5.257 | |
| Random effects | ||||
| Interindividual variability | ||||
| ωCL2 | 0.276 (20) [1] | 0.0523 (33) [8] | 0.0544 | 0.017, 0.129 |
| ωV12 | 0.313 (49) [32] | 0.291 (65) [31] | 0.431 | 0.083, 1.279 |
| ωV22 | 0.0898 (51) [45] | 0.138 (34) [28] | 0.115 | 0.013, 0.325 |
| Residual variability | ||||
| σ2proportional | 0.107 (26) [7] | 0.0979 (20) [8] | 0.0874 | 0.055, 0.126 |
a
RSE %, relative standard error; RSE % = (standard error/parameter estimate) × 100; CI, confidence interval; CL, systemic clearance; V1, central volume of distribution; V2, peripheral volume of distribution; Q, intercompartmental clearance; ECMO, extracorporeal membrane oxygenation therapy; CrCL, creatinine clearance; CVVHDF, continuous venovenous hemodiafiltration.